Log in or Sign up for Free to view tailored content for your specialty!
Infection News
Long term autoimmune, autoinflammatory disease risk significantly higher after COVID-19
SARS-CoV-2 infection, especially a severe case or without vaccination, significantly increases the long-term risk for developing autoimmune and autoinflammatory connective tissue diseases, according to data published in JAMA Dermatology.
Severe infection, rituximab use predict long COVID in patients with autoimmune disease
WASHINGTON — Severe acute COVID-19 infection, as well as glucocorticoid and rituximab use, increase the risk for long COVID in patients with autoimmune rheumatic diseases, according to data presented at ACR Convergence 2024.
Post-exertional malaise assessment ‘becoming more important’ for long COVID in rheum care
WASHINGTON — Approximately 20% of patients meeting the 2016 fibromyalgia criteria report post-exertional malaise, which itself may be key to understanding both long COVID and fatigue in patients with rheumatic diseases, according to data.
Log in or Sign up for Free to view tailored content for your specialty!
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
WASHINGTON — The correlation between autoantibodies and new-onset autoimmune disease in individuals with long COVID symptoms remains “controversial,” according to a speaker at ACR Convergence 2024.
Low IL-18 levels may predict long COVID risk in systemic autoimmune rheumatic diseases
WASHINGTON — Among patients with systemic autoimmune rheumatic diseases, circulating interleukin-18 levels were lower in those with long COVID vs. those without, according to data presented at ACR Convergence 2024.
IL-6, JAK inhibitors, rituximab increase severe infection risk in inflammatory arthritis
WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.
Withholding JAK, IL-17 inhibitors fails to improve COVID-19 vaccine booster response
WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or spondyloarthritis does not significantly benefit COVID-19 booster response, according to data presented at ACR Convergence 2024.
Herpes zoster vaccine effective, shows ‘no signs’ of increased severe flare risk in lupus
WASHINGTON — Herpes zoster vaccination is effective in patients with systemic lupus erythematosus and multiple sclerosis, without increasing the risk for severe lupus flares, according to data presented at ACR Convergence 2024.
Rheumatic disease activity at time of COVID-19 vaccination drives subsequent flare risk
Higher disease activity and medication reduction at COVID-19 vaccination increase the risk for subsequent flares in patients with rheumatic and musculoskeletal diseases, according to data published in Annals of the Rheumatic Diseases.
Rural patients with AIRDs have 24% higher post-COVID mortality risk vs urban population
Patients with autoimmune or inflammatory rheumatic diseases living in rural areas demonstrate a 24% higher mortality risk after SARS-CoV-2 infection vs. those in urban areas, according to data published in Arthritis Care & Research.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read